Invasive fungal infections in <scp>AML</scp> / <scp>MDS</scp> patients treated with azacitidine: a risk worth considering antifungal prophylaxis?

Helena Pomares(Duran i Reynals Hospital), Rafael F. Duarte(Institut Català d'Oncologia), Isabel Sánchez‐Ortega(European Society for Blood and Marrow Transplantation), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Montserrat Arnán(Duran i Reynals Hospital)
Mycoses
March 30, 2016
10.1111/myc.12500
Cited by 47

Related Papers

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2015|740
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718